Maria C. McGreevy

Maria C. McGreevy, M.D., is a physician scientist affiliated with the University of Rochester Medical Faculty Group (URMFG) and the Wilmot Cancer Institute, specializing in Hematology & Oncology. She is part of Accountable Health Partners (AHP), a regional network of over 2,000 providers. Her clinical focus includes cancer care and hematology, with expertise in targeted therapies and translational research.

• Education: MD from SUNY Upstate Medical University College of Medicine (2016).
• Residency: Internal Medicine at University of Virginia (2016-2019).
• Fellowship: Hematology & Oncology at University of Rochester Medical Center (2019-2022).

Maria’s research centers on molecular mechanisms in hematologic malignancies, including signal transduction pathways (STAT3/STAT5), pharmacodynamic analyses of inhibitors, and translational applications in leukemia and breast cancer. Her work bridges preclinical models and clinical trials, particularly for Acute Myelogenous Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL).

Her recent publications highlight therapeutic strategies for colon cancer guided by circulating tumor DNA (ctDNA) evaluation, STAT3 inhibition in CLL, and BCL6 targeting in breast cancer. Key subfields span tyrosine kinase inhibition, stromal interactions in AML, and pharmacodynamic biomarker development.

• 2024: Oncology Teacher of the Year Award.
• 2021: Segel/Haterman Fellowship Award and Hematology Oncology Chief Fellow.
• 2019: First Place Oral Presentation at ACP Virginia Resident Abstract Competition.
• 2015: Alpha Omega Alpha Society Membership.

As a lead researcher on a Phase II/III trial for colon cancer, Maria collaborates with interdisciplinary teams at Wilmot Cancer Institute, focusing on personalized chemotherapy regimens based on residual disease markers.